Display Mode
Dark
Dark
Light
Light
Theme Cover
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Search History
No search history
Copied to clipboard
StarredCase saved
Oh No!
Copied to clipboard
StarredCase saved
Oh No!
Media
Term
Opinion Writer
Direction
Field

Merck & Co., Inc., Et Al. v. Richard Reynolds Et Al.

• 2009 • 559 U.S. 633 • Roberts Court
In the 2009 case of Merck & Co., Inc. v. Richard Reynolds, the U.S. Supreme Court addressed issues related to statute of limitations in securities fraud cases under federal law. The plaintiffs, investors in Merck's stock, alleged that the company had misled them about potential liabilities associated with its painkiller drug Vioxx and filed a lawsuit after they learned about these risks from an FDA warning letter issued to Merck in 2001 and subsequent events leading up to Vioxx’s withdrawal...Open Case
Score:
Copyright © 2026Etalia.ai All Rights Reserved
  • Blog
  • •
  • Privacy
  • •
  • Terms
1 results found
Become a Sponsor
Support Us
Feedback: We can do better!

Your feedback is extremely important to us and greatly appreciated.
Tell us what went wrong

Copied to clipboard
StarredCase saved
Oh No!
Chief Roberts Court
Term: 2009
Docket: 08-905
559 U.S. 633
130 S. Ct. 1784
176 L. Ed. 2d 582
2010 U.S. LEXIS 3671
Argued: Nov 30, 2009

Merck & Co., Inc., Et Al. v. Richard Reynolds Et Al.

  • Pro
  • Pro
Go Pro!orto acess these features and extra content.

Questions presented:
SCOTUS Records

08-905 MERCK & CO., INC. V. REYNOLDS DECISION BELOW: 543 F.3d 150 CERT. GRANTED 5/26/2009 QUESTION PRESENTED: Did the Third Circuit err in holding, in accord with the Ninth Circuit but in contrast to nine other Courts of Appeals, that under the "inquiry notice" standard applicable to federal securities fraud claims, the statute of limitations does not begin to run until an investor receives evidence of scienter without the benefit of any investigation? LOWER COURT CASE NUMBER: 07-2431. 07-2432

Opinion Summary
AI Abstract

In the 2009 case of Merck & Co., Inc. v. Richard Reynolds, the U.S. Supreme Court addressed issues related to statute of limitations in securities fraud cases under federal law. The plaintiffs, investors in Merck's stock, alleged that the company had misled them about potential liabilities associated with its painkiller drug Vioxx and filed a lawsuit after they learned about these risks from an FDA warning letter issued to Merck in 2001 and subsequent events leading up to Vioxx’s withdrawal from market in 2004 due to safety concerns. However, Merck argued that their claim was time-barred because it was not brought within two years "after discovery" of facts constituting violation as required by law. The Supreme Court held that for purposes of this two-year limit on filing claims (statute of limitations), 'discovery' includes not only when plaintiff becomes aware of certain facts suggesting wrongdoing but also when he should have discovered through reasonable diligence all essential elements needed for his claim including defendant's intent or scienter - which is often last fact plaintiff learns since it relates more to what defendant knew than what he did or failed do. Therefore, even though some relevant information might have been available earlier via FDA warning letter etc., full extent and nature of alleged misrepresentation could only be known later once more details emerged regarding Vioxx’s health risks and how much company knew about them beforehand; hence suit wasn't late-filed as per court ruling.

Dissent Summary
AI Abstract

In the dissenting opinion for Merck & Co., Inc. v. Richard Reynolds et al., Justice Scalia argued that the majority's interpretation of the statute of limitations was incorrect and overly broad. He contended that under a proper reading of the law, plaintiffs should have been aware they had a claim when they suffered an economic loss due to Merck’s alleged misrepresentation about its drug Vioxx, not when they became aware that this conduct might be legally actionable as fraud. This would mean their lawsuit was filed too late and should be dismissed on those grounds alone. Furthermore, he criticized the majority's decision as creating unnecessary confusion by introducing subjective elements into what should be an objective analysis based on known facts rather than potential legal theories or outcomes.

Opinion written by Justice SGBreyer
Decided: Apr 27, 2010
PDF viewer is not available.
Oral Transcript
Argued: Oct 05, 2026
Go Pro!orto acess these features and extra content.
Related Cases
AI Assist
Go Pro!orto acess these features and extra content.
PDF viewer is not available.
Oral Transcripts
Go Pro!orto acess these features and extra content.
Related Cases
Go Pro!orto acess these features and extra content.
Ask Etalia.ai
Go Pro!orto acess these features and extra content.
Audio of Oral Arguments
Free Trial!
Become a Sponsor

Support Us
Copyright © 2026Etalia.ai All Rights Reserved
  • Blog
  • •
  • Privacy
  • •
  • Terms